Rein Therapeutics, Inc. Stock: price and insider trades · United States

Rein Therapeutics, Inc. (NASDAQ: RNTX) is a U.S.-listed biopharmaceutical company headquartered in Austin, Texas, focused on orphan pulmonary and fibrotic diseases. The company was previously known as Aileron Therapeutics, Inc. and rebranded to Rein Therapeutics in January 2025, with its common stock beginning to trade under the RNTX symbol on the NASDAQ. For investors, Rein should be viewed as a clinical-stage biotech with a concentrated asset base and a valuation that is primarily driven by clinical milestones, regulatory progress, and financing execution rather than product revenue.

Rein’s business model centers on developing first-in-class medicines for significant unmet medical needs in pulmonary fibrosis and related indications. Its lead program is LTI-03, an inhaled therapy being developed for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. In March 2026, the company announced that it had dosed the first patient in its Phase 2 RENEW trial, following recent FDA clearance to resume the U.S. program. Rein describes LTI-03 as a multi-pathway, caveolin-1-related peptide intended to regulate fibrosis pathways and help preserve lung function. The company’s second key asset is LTI-01, being advanced for loculated pleural effusion (LPE), another orphan pulmonary indication with meaningful unmet need.